Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00185692 · ClinicalTrials.gov registry record · Phase 2
Allogeneic Transplantation From Related Haploidentical Donors
A Phase 2 study of Leukemia and Graft-Versus-Host Disease, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT00185692: Completed Phase 2 study of Leukemia and Graft-Versus-Host Disease, sponsored by Stanford University.
NCT00185692 is a Phase 2 study of Leukemia and Graft-Versus-Host Disease that has completed, run by Stanford University. The registered enrollment target is 16 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00185692, a Phase 2 study of Leukemia and Graft-Versus-Host Disease, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate the feasibility and safety of transplanting CD34+ selected hematopoietic cells from a haploidentical related donor following a nonmyeloablative regimen of total lymphoid irradiation (TLI) and antithymocyte globulin (ATG).
Primary Outcome
number achieving donor cell engraftment (\>95%) by day 90 after transplant.
Conditions Studied
Interventions
- DRUG G-CSF
- DRUG Mycophenolate Mofetil
- DRUG Cyclosporine
- PROCEDURE non-myeloablative hematopoietic cell transplantation
- DRUG Anti-Thymocyte Globulin
Study Locations (1)
California
- Stanford University School of Medicine - Stanford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2000-08 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
What the finished NCT00185692 record still lists
NCT00185692 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (97% lower).
The record links to 8 conditions, with Leukemia appearing as the primary indexed condition, and to 5 interventions - of which G-CSF is the first listed.
NCT00185692 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00185692 about?
NCT00185692 is a clinical study titled "Allogeneic Transplantation From Related Haploidentical Donors". The purpose of the study is to evaluate the feasibility and safety of transplanting CD34+ selected hematopoietic cells from a haploidentical related donor following a nonmyeloablative regimen of total lymphoid irradiation (TLI) and antithymocyte globulin (ATG).
What is the current status of trial NCT00185692?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2000-08. Estimated completion is 2010-12.
What conditions does trial NCT00185692 study?
This clinical trial studies the following conditions: Leukemia, Graft-Versus-Host Disease, MDS, Hodgkin's Disease, Blood Cancer.
What interventions are being tested in trial NCT00185692?
The interventions under investigation include: G-CSF (DRUG), Mycophenolate Mofetil (DRUG), Cyclosporine (DRUG), non-myeloablative hematopoietic cell transplantation (PROCEDURE), Anti-Thymocyte Globulin (DRUG).
Who is sponsoring clinical trial NCT00185692?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00185692 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00185692's enrollment target sits among peer trials
16 195th of 233 higher than 31 of 233 other Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
RECRUITING · Phase 2
-
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
RECRUITING · Phase 2
-
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 2
-
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
RECRUITING · Phase 2
-
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia